3 recruiting, 2 not yet recruiting, 1 active not recruiting, 1 completed. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 3, Not yet recruiting 2, Active not recruiting 1, Completed 1, Enrolling by invitation 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Alzheimer Disease (AD): new trials by email Literature Review of Alzheimer Disease (AD) trials Research Report on Alzheimer Disease (AD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease Nicotinamide Riboside (NR), Palacebo - Alzheimer Disease (AD) | Phase 2 | Recruiting | Haukeland University Hospital | 270 | 2026-08-26 | 2026-08-20 |
| [18F]F-AraG PET Imaging in Alzheimer's Disease Drug: [18F]F-AraG (PET tracer) - Alzheimer Disease (AD) | Phase 2 | Not yet recruiting | CellSight Technologies, Inc. | 10 | 2026-05-16 | 2026-05-28 |
| Improved Treatment and Monitoring of Alzheimer's Disease Semaglutide (Rybelsus®) combined with other interventions, Placebo, Semaglutide (Rybelsus®) - Alzheimer Disease (AD) | Phase 2 | Not yet recruiting | Rune Skovgaard Rasmussen | 180 | 2026-01-01 | 2025-08-22 |
| Daridorexant for Alzheimer Disease Prevention Daridorexant 50 mg, Placebo - Alzheimer Disease (AD) | Phase 2 | Recruiting | Douglas Mental Health University Institute | 240 | 2025-10-14 | 2025-12-19 |
| Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase Cannabis 50 mg of CBD and 5 mg of THC - Alzheimer Disease (AD) | Phase 1 / Phase 2 | Active not recruiting | Federal University of Latin American Integration | 61 | 2025-04-07 | 2025-08-12 |
| A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI Ginkgo Biloba Extract 761 - Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) | Phase 2 | Enrolling by invitation | Hadassah Medical Organization | 50 | 2024-08-20 | 2025-12-17 |
| Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers 18F-OP-801 - Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD) | Phase 1 / Phase 2 | Recruiting | Ashvattha Therapeutics, Inc. | 65 | 2023-02-02 | 2025-05-02 |
| A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease Zagotenemab, Placebo - Alzheimer Disease (AD) | Phase 2 | Completed | Eli Lilly and Company | 360 | 2018-04-30 | 2022-08-30 |
Alzheimer Disease (8) · Cognitive Dysfunction (4) · Dementia (2) · Amyotrophic Lateral Sclerosis (1) · Memory Disorders (1) · Multiple Sclerosis (1) · Parkinson Disease (1) · Pick Disease of the Brain (1) · Tauopathies (1)
Brain Diseases (8) · Central Nervous System Diseases (8) · Mental Disorders (8) · Nervous System Diseases (8) · Neurocognitive Disorders (8) · Neurodegenerative Diseases (8) · Tauopathies (7) · Dementia (6) · Cognition Disorders (4) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Basal Ganglia Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Frontotemporal Dementia (1)
Calcium (1) · Dronabinol (1) · Ginkgo biloba extract (1) · Pharmaceutical Preparations (1) · candesartan (1) · daridorexant (1) · nabiximols (1) · nicotinamide-beta-riboside (1) · semaglutide (1)
Ashvattha Therapeutics, Inc. (1) · CellSight Technologies, Inc. (1) · Douglas Mental Health University Institute (1) · Eli Lilly and Company (1) · Federal University of Latin American Integration (1) · Hadassah Medical Organization (1) · Haukeland University Hospital (1) · Rune Skovgaard Rasmussen (1)
Canada (2) · United States (2) · Brazil (1) · Israel (1) · Japan (1) · Norway (1)
Farshad Moradi, MD (1) · Kristoffer Haugarvoll, MD, PhD (1) · Sylvia Villeneuve, PhD (1)